/
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.
11.17% operating margin is respectable but not wide. ROIC at 4.34%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 16.0% YoY with margins expanding 7.6pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$542M
▲ +16.0% YoY
Net Income (TTM)
$88M
▲ +174.9% YoY
Op. Margin
14.31%
▲ +7.6pp YoY
ROIC
5.64%
▲ +3.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$155M
▲ +98.5% YoY
Op. Cash Flow (TTM)
$166M
▲ +81.5% YoY
Net Debt
-$224M
Net Cash Position
Cash & Equiv.
$263M
5Y CAGR: +34.5%
Continue Research